Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032463 (polycythemia vera)
 3,374 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

T-lymphocyte function was investigated in a group of eight patients with polycythemia vera (PV) and 13 normals. Responsiveness of T-cells to stimulation by mitogen was significantly impaired in the PV patients (p = .02). Analysis of immune cell subpopulation composition by assessment of cell surface phenotype did not reveal imbalances that could account for impaired T-cell proliferative ability in PV patients. Addition of recombinant human interleukin-1 to PV mononuclear cell cultures did not enhance proliferative ability. Addition of recombinant human interleukin-2 to cultures had no effect on maximum mitogen stimulation in normals but significantly improved responses in PV patients (p less than .02), correcting them to normal levels. Measurement of interleukin-2 production by stimulated cultured mononuclear cells confirmed subnormal IL-2 production by PV T-cells (p less than .00005). Impaired IL-2 production could conceivably contribute to the pathogenesis of PV by limiting the ability of IL-2-dependent cells to regulate hematopoiesis.
 ...
PMID:Impaired interleukin-2 production by T-lymphocytes in polycythemia vera. 278 60

Three candidate cytokines: recombinant porcine interleukin-2 (rpIL-2), rpIL-6 and the fusion protein rpIL6-IL2 were used as adjuvants in this study to investigate the enhanced immune responses to PRV inactivated vaccine (IAV) in pigs. In this natural host trial, we demonstrated that rpIL-2 showed potential adjuvant effects on PRV IAV, which was characterized not only in antigen-specific immune responses, but also in protection against PRV infection. The use of rpIL-2 resulted in significantly higher virus neutralizing (VN) antibody levels and CTL activities on PRV IAV vaccination. The increased PRV-specific secretion of pIL-4 and pIFN-gamma from PBMC of pigs also demonstrated the adjuvant effects of rpIL-2. In addition, the co-administration of the rpIL-2 also produced an improved protection to the viral challenge, demonstrated by significant reduction of the ratios of fever and viral excretion in nasal swabs. However, there was no additional effect of adjuvant induced enhancement of immune responses and protection against challenge with the use of rpIL-6 and rpIL6-IL2 in this study.
 ...
PMID:The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs. 1594 76